Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 7, 2014, Pages 853-859

  Zelner, Jonathan L ^a,b   Murray, Megan B ^c,d   Becerra, Mercedes C ^c,e,f   Galea, Jerome ^e   Lecca, Leonid ^e   Calderon, Roger ^e   Yataco, Rosa ^e   Contreras, Carmen ^e   Zhang, Zibiao ^f   Grenfell, Bryan T ^a,b   Cohen, Ted ^d,f  

^a PRINCETON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e PARTNERS IN HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bacillus Calmette Gu rin vaccination; Household intervention; Isoniazid preventive therapy; Tuberculosis

Indexed keywords

BCG VACCINE; ISONIAZID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BCG VACCINATION; CHILD; DRUG EFFICACY; FEMALE; FOLLOW UP; HOUSEHOLD; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; PERU; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BCG VACCINE; CHILD; CHILD, PRESCHOOL; CONTACT TRACING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; ISONIAZID; MALE; MIDDLE AGED; MODELS, STATISTICAL; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; ODDS RATIO; PERU; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84897448355     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201310-1896OC     Document Type: Article

References (18)

1. World Health Organization. Global tuberculosis report 2012. Geneva: World Health Organization; 2012.
2. Kranzer K, Afnan-Holmes H, Tomlin K., Golub JE, Shapiro AE, Schaap A, Corbett E.L., Lönnroth K, Glynn JR. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis 2013; 17:432-446.
3. Lönnroth K, Corbett E, Golub J, Godfrey-Faussett P, Uplekar M, Weil D, Raviglione M. Systematic screening for active tuberculosis: rationale, definitions and key considerations. Int J Tuberc Lung Dis 2013; 17: 289-298.
4. Fox GJ, Barry SE, Britton W.J., Marks GB Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2012; 41:140-156.
5. Shapiro AE, Variava E, Rakgokong M.H., Moodley N., Luke B, Salimi S, Chaisson R.E., Golub JE, Martinson NA. Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med 2012; 185:1110-1116.
6. Morrison J, Pai M, Hopewell PC Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:359-368.
7. World Health Organization. Recommendations for investigating contacts of person with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012.
8. World Health Organization Stop TB Partnership Childhood TB Subgroup. Chapter 4: childhood contact screening and management. Int J Tuberc Lung Dis 2007; 11:12-15.
9. Mangtani P, Abubakar I, Ariti C., Beynon R, Pimpin L, Fine PEM, Rodrigues LC, Smith PG, Lipman M, Whiting PF, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014; 58:470-480.
10. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva: World Health Organization; 2013.
11. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50:90-106.
12. Floyd S, Ponnighaus JM, Bliss L, Warndorff D.K., Kasunga A., Mogha P, Fine PE BCG scars in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int J Tuberc Lung Dis 2000; 4:1133-1142.
13. Population Reference Bureau. 2006 World population data sheet. Washington, DC: 2006.
14. Shah S, Yuen CM, Heo M, Tolman A.W., Becerra MC Yield of contact investigations in households of drug-resistant tuberculosis patients: systematic review and meta-analysis. Clin Infect Dis 2014; 58:381-391.
15. Bates D, Maechler M, Ben Bolker, Walker S. Lme4: Linear mixed-effects models using Eigen and S4. R package version 1.0-5. 2013 [accessed 2013 Aug 1]. Available from: http://cran.r-project.org/package=lme4
16. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-1180.
17. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-1345.
18. Aronson NE, Santosham M, Comstock G.W., Howard RS, Moulton LH, Rhoades ER, Harrison LH Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 2004; 291:2086-2091.